Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules

Molecular Carcinogenesis

Volumn 54, Issue 7, 2015, Pages 554-565

  Ramteke, Anand ^a,b   Ting, Harold ^a   Agarwal, Chapla ^a,c   Mateen, Samiha ^a   Somasagara, Ranganathan ^a   Hussain, Anowar ^b   Graner, Michael ^d   Frederick, Barbara ^a,c   Agarwal, Rajesh ^a,c   Deep, Gagan ^a,c  

^a UNIVERSITY OF COLORADO   (United States)

^b TEZPUR UNIVERSITY   (India)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Adherens junction; Exosomes; Hypoxia; Invasiveness; Prostate cancer

Indexed keywords

BETA CATENIN; CD63 ANTIGEN; CD81 ANTIGEN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; INTEGRIN LINKED KINASE; INTERLEUKIN 6; LIPOCORTIN 2; METALLOPROTEINASE; NANOPARTICLE; OXYGEN; PROTEIN KINASE B; PROTEOME; TETRASPANIN; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR 1 ALPHA; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; UNCLASSIFIED DRUG; HEAT SHOCK PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL COMMUNICATION; CELL FUNCTION; CELL HYPOXIA; CELL INVASION; CELL JUNCTION; CELL MIGRATION; CELL MOTILITY; COCULTURE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; EXOSOME; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LNCAP CELL LINE; MALE; PARTICLE SIZE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR INVASION; TUMOR MICROENVIRONMENT; ADHERENS JUNCTION; ANOXIA; CELL MOTION; COMPLICATION; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADHERENS JUNCTIONS; ANNEXIN A2; ANOXIA; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; COCULTURE TECHNIQUES; EXOSOMES; HEAT-SHOCK PROTEINS; HUMANS; MALE; METALLOPROTEASES; NEOPLASM INVASIVENESS; PROSTATE; PROSTATIC NEOPLASMS; PROTEOME; SIGNAL TRANSDUCTION; TETRASPANINS;

EID: 84930763705     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22124     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30.
2. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther 2007; 6:2609-2617.
3. Tantivejkul K, Kalikin LM, Pienta KJ. Dynamic process of prostate cancer metastasis to bone. J Cell Biochem 2004; 91:706-717.
4. Hadaschik BA, Gleave ME. Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol 2007; 25:413-419.
5. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007; 7:139-147.
6. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005; 7:513-520.
7. Deep G, Agarwal R. Targeting tumor micro environment with silibinin: Promise and potential for a translational cancer chemopreventive strategy. Curr Cancer Drug Targets 2013; 13:486-499.
8. Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: A comprehensive review. Cancer Metastasis Rev 2013; 32:623-642.
9. Sceneay J, Smyth MJ, Moller A. The pre-metastatic niche: Finding common ground. Cancer Metastasis Rev 2013; 32:449-464.
10. Keller S, Sanderson MP, Stoeck A, Altevogt P. Exosomes: From biogenesis and secretion to biological function. Immunol Lett 2006; 107:102-108.
11. Epple LM, Griffiths SG, Dechkovskaia AM, et al. Medulloblastoma exosome proteomics yield functional roles for extracellular vesicles. PLoS ONE 2012; 7:e42064.
12. Hosseini-Beheshti E, Pham S, Adomat H, Li N, Tomlinson Guns ES. Exosomes as biomarker enriched microvesicles: Characterization of exosomal proteins derived from a panel of prostate cell lines with distinct AR phenotypes. Mol Cell Proteomics 2012; 11:863-885.
13. Peinado H, Aleckovic M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012; 18:883-891.
14. Bao B, Ahmad A, Kong D, et al. Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS ONE 2012; 7:e43726.
15. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006; 82:699-757.
16. Dai Y, Bae K, Siemann DW. Impact of hypoxia on the metastatic potential of human prostate cancer cells. Int J Radiat Oncol Biol Phys 2011; 81:521-528.
17. Butterworth KT, McCarthy HO, Devlin A, et al. Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype. Int J Cancer 2008; 123:760-768.
18. Fiaschi T, Giannoni E, Taddei ML, et al. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle 2013; 12:1791-1801.
19. Giannoni E, Bianchini F, Masieri L, et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res 2010; 70:6945-6956.
20. Deep G, Gangar SC, Agarwal C, Agarwal R. Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. Cancer Prev Res (Phila) 2011; 4:1222-1232.
21. Shevchenko A. Evaluation of the efficiency of in-gel digestion of proteins by peptide isotopic labeling and MALDI mass spectrometry. Anal Biochem 2001; 296:279-283.
22. Luo Y, He DL, Ning L, et al. Hypoxia-inducible factor-1 alpha induces the epithelial-mesenchymal transition of human prostatecancer cells. Chin Med J 2006; 119:713-718.
23. Mimeault M, Batra SK. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med 2013; 17:30-54.
24. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-715.
25. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9:265-273.
26. Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 2009; 19:683-697.
27. Guzman-Ramirez N, Voller M, Wetterwald A, et al. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate 2009; 69:1683-1693.
28. Kojima Y, Acar A, Eaton EN, et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA 2010; 107:20009-20014.
29. Miyamoto H, Altuwaijri S, Cai Y, Messing EM, Chang C. Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: Potential therapeutic approaches for prostate cancer. Mol Carcinog 2005; 44:1-10.
30. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008; 14:2519-2526.
31. Erler JT, Bennewith KL, Cox TR, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009; 15:35-44.
32. Wong CC, Gilkes DM, Zhang H, et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci USA 2011; 108:16369-16374.
33. Sceneay J, Chow MT, Chen A, et al. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res 2012; 72:3906-3911.
34. King HW, Michael MZ, Gleadle JM. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 2012; 12:421.
35. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007; 39:305-318.
36. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006; 66:8319-8326.
37. Baranwal S, Alahari SK. Molecular mechanisms controlling E-cadherin expression in breast cancer. Biochem Biophys Res Commun 2009; 384:6-11.
38. Inge LJ, Rajasekaran SA, Wolle D, et al. alpha-Catenin overrides Src-dependent activation of beta-catenin oncogenic signaling. Mol Cancer Ther 2008; 7:1386-1397.
39. Ebnet K. Organization of multiprotein complexes at cell-cell junctions. Histochem Cell Biol 2008; 130:1-20.
40. Onder TT, Gupta PB, Mani SA, et al. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008; 68:3645-3654.
41. Umbas R, Isaacs WB, Bringuier PP, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994; 54:3929-3933.
42. Umbas R, Schalken JA, Aalders TW, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992; 52:5104-5109.
43. Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG. Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 1996; 148:1375-1380.
44. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138:645-659.